New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 20, 2014
11:14 EDTVRX, AKRXAkorn sells ECR Pharmaceuticals unit to Valeant for $41M
Akorn (AKRX) announced that it has sold its subsidiary, ECR Pharmaceuticals, to Valeant Pharmaceuticals (VRX) for $41M in cash and assumption of certain liabilities. ECR, which promotes certain branded pharmaceuticals through its sales force, was acquired through the acquisition of Hi-Tech Pharmacal. In light of this divestiture, Akorn will update its annual 2014 guidance during its Q2 earnings call in early August.
News For AKRX;VRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
08:05 EDTVRXValeant outlook has improved, says RBC Capital
Subscribe for More Information
December 17, 2014
10:53 EDTVRXAckman says 'will take hard look' at Valeant shares after restrictions end
Subscribe for More Information
December 9, 2014
10:23 EDTAKRXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:31 EDTVRXZoetis drops after report of Valeant abandoning growth by acquisitions strategy
Subscribe for More Information
07:11 EDTAKRXAkorn initiated with Outperform, $50 target at William Blair
William Blair started shares of Akorn with an Outperform rating and $50 price target. The firm says the maker of ophthalmic and hospital-based injectable therapies is one of the fastest-growing companies in the specialty pharmaceuticals sector. William Blair thinks consolidation will likely continue within the specialty/generics market and feels Akorn represents an attractive asset. The stock closed yesterday up 38c to $39.75.
06:39 EDTVRXValeant to abandon growth by acquisitions strategy, Reuters says
Subscribe for More Information
December 8, 2014
11:30 EDTAKRXLeerink generics pharmaceutical analyst holds analyst/industry conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use